UPDATE: JPMorgan Downgrades Y-mAbs Therapeutics (YMAB) to Underweight
Tweet Send to a Friend
(Updated - October 31, 2022 5:35 AM EDT)
JPMorgan analyst Tessa Romero downgraded Y-mAbs Therapeutics (NASDAQ: YMAB) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Tessa Romero downgraded Y-mAbs Therapeutics (NASDAQ: YMAB) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
